Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals, Inc. et al
| Otsuka Pharmaceutical Co., Ltd. |
| Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. |
| 1:2022cv00513 |
| April 22, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 20, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 11
SO ORDERED Granting #10 Stipulation and Proposed Order (*Party Teva Pharmaceutical Industries Ltd. terminated). Signed by Judge Richard G. Andrews on 6/2/2022. (nms)
|
| Filing 10 STIPULATION and Proposed Order of Dismissal, by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Keller, Karen) Modified on 6/2/2022 (nms). |
| Filing 9 WAIVER OF SERVICE returned executed by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc.: For Teva Pharmaceuticals, Inc. waiver sent on 5/13/2022, answer due 7/12/2022; Teva Pharmaceuticals USA, Inc. waiver sent on 5/13/2022, answer due 7/12/2022. (Keller, Karen) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 8 Summons Issued as to Teva Pharmaceuticals USA, Inc. on 4/22/2022. (srs) |
| Filing 7 Summons Issued as to Teva Pharmaceutical Industries Ltd. on 4/22/2022. (srs) |
| Filing 6 Summons Issued as to Teva Pharmaceuticals, Inc. on 4/22/2022. (srs) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Otsuka Pharmaceutical Co., Ltd. filed by Otsuka Pharmaceutical Co., Ltd. (srs) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,501,730 B2 ;10,905,694 B2 ;8,273,735 B2. (srs) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: March 9, 2022. Date of Expiration of the 730 Patent: September 1, 2026. Date of Expiration of the 694 Patent: April 7, 2030. Date of Expiration of the 735 Patent: August 14, 2028.Thirty Month Stay Deadline: September 9, 2024. (srs) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3857538.) - filed by Otsuka Pharmaceutical Co., Ltd.. (Attachments: #1 Exhibit A-c , #2 Civil Cover Sheet)(srs) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
